相关临床试验
319
36 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1819
进行中（未招募）
27
8.5%
已完成
178
55.8%
Enrolling By Invitation
2
0.6%
尚未招募
7
2.2%
招募中
36
11.3%
暂停
1
0.3%
终止
19
6.0%
Unknown
32
10.0%
撤回
17
5.3%
暂无批准数据
- The Leukemia Research Foundation has awarded funding to a University of Cincinnati study investigating RhoA as a therapeutic target in TP53-mutated acute myeloid leukemia (AML). - Patients with TP53-mutated leukemia often respond poorly to available treatments, with survival typically measured in months, underscoring an urgent unmet need. - Preliminary research identified RhoA as a potential key driver of drug resistance in TP53-mutant AML, and it can be blocked with experimental drugs. - The study will test whether blocking RhoA sensitizes TP53-mutant AML cells to existing therapies using cell, animal, and patient-donated samples.
- ADLM 2026 convenes July 26–30 in Anaheim, California, bringing together nearly 17,000 global leaders in clinical laboratory medicine. - Dr. David M. Nathan will open the meeting reflecting on five decades of diabetes research, including his pioneering work establishing hemoglobin A1c as the gold-standard test and the role of GLP-1 in glucose regulation. - Dr. Elizabeth Head will present her 25-year investigation into the Alzheimer's–Down syndrome connection, exploring intervention targets that may inform precision medicine for the broader aging population. - Dr. Arun Wiita will close the conference with mass spectrometry-based discovery of novel cancer biomarkers on blood cancer cell membranes, with potential to yield new immune-based therapies.
- The phase III FASTEST trial found that recombinant factor VIIa reduced hematoma growth when given within 2 hours of intracerebral hemorrhage onset but failed to improve overall functional outcomes. - Treatment significantly increased life-threatening thromboembolic complications (4.6% vs 1.3%) while showing promising signals in patients treated within 90 minutes or those with positive spot signs on CT angiography. - FASTEST Part 2 is now underway, focusing specifically on these higher-response subgroups to evaluate whether ultra-early hemostatic therapy can achieve meaningful clinical benefits.
- Polarean announced expansion of its Xenon MRI platform into cardiopulmonary pharma-sponsored drug development through a multi-center U.S. study in pulmonary hypertension with interstitial lung disease (PH-ILD). - The researcher-led study will use Xenon MRI-derived biomarkers to evaluate an inhaled therapy designed to address both pulmonary vascular dysfunction and interstitial lung disease. - Xenon MRI is the only imaging modality that specifically probes pulmonary capillaries, previously a "silent zone" that could not be measured directly with existing diagnostic tools. - The innovative trial design captures both acute (within minutes) and chronic (over 12 weeks) treatment effects, providing direct insight into cardiopulmonary physiology at the drug delivery site.
- The University of Cincinnati is leading a multicenter clinical trial to test extended oral tranexamic acid (TXA) dosing for seven days after ACL reconstruction surgery to improve recovery outcomes. - The randomized controlled trial will enroll 100 participants aged 14-22 across six medical centers, comparing extended TXA treatment to placebo for post-surgical recovery. - Extended TXA dosing has shown improved results in joint replacement procedures and may reduce pain, swelling, and promote earlier movement in ACL patients. - Researchers expect the treatment could prevent arthrogenic muscle inhibition and allow athletes to return to sports sooner than the typical 9-12 month recovery period.
- University of Cincinnati startup RNA Nanotherapeutics has developed multifunctional RNA nanoparticles that precisely target MED1 protein to overcome tamoxifen resistance in breast cancer patients. - Preclinical studies demonstrate superior tumor-specific targeting and efficacy compared to current treatments, with no toxicity observed even at 10 times the effective dose. - The company aims to advance its breast cancer therapy into clinical trials within five years and has secured multiple funding awards including Ohio's Third Frontier TVSF Phase 2 award. - MED1 protein levels are abnormally high in 40%-60% of breast cancers and are associated with adverse treatment outcomes, making it a critical therapeutic target.
- The University of Cincinnati Gardner Neuroscience Institute is participating in an international Phase 2 trial testing a novel oral drug that enhances endocannabinoids to treat muscle spasticity in multiple sclerosis patients. - The investigational therapy works by inhibiting two enzymes (MAGL and FAAH) that break down naturally occurring endocannabinoids, allowing these molecules to better regulate overly reactive spastic muscles. - The multicenter trial will randomize approximately 200 MS patients across multiple sites to receive one of three drug doses or placebo daily for six weeks, with an optional additional six-week extension period. - Current oral medications for spasticity have significant limitations including drowsiness side effects, and no new effective oral treatments have been developed in the United States over the past 20-30 years.
- Researchers have discovered that AM-101, a synthetic benzodiazepine analog, can enhance the efficacy of radiation therapy for lung cancer that has metastasized to the brain. - AM-101 activates GABA(A) receptors in NSCLC cells, promoting autophagy and increasing the sensitivity of cancer cells to radiation treatment. - Animal models demonstrated that AM-101, combined with radiation, significantly improves survival rates and slows the growth of both primary NSCLC and brain metastases. - Phase 1 clinical trials are planned to test the combination of AM-101 and radiation in lung cancer patients with and without brain metastases.
- A recent study identifies progesterone, specifically Provera, as a significant risk factor for vision loss related to meningiomas in premenopausal women. - Researchers are now conducting tests on patient samples to determine the prevalence of progesterone receptor expression in meningiomas. - The study emphasizes the importance of age-appropriate counseling and consistent assessment of hormone receptor status in meningiomas. - Clinicians have begun informing patients about the risks associated with Provera, leading many to discontinue its use.
• New research suggests Alzheimer's drugs like lecanemab and donanemab may slow disease progression by increasing levels of healthy amyloid beta (Aβ42) protein in the brain. • The study challenges the prevailing theory that these drugs work solely by reducing toxic amyloid plaques, highlighting the potential importance of soluble Aβ42 in maintaining brain health. • Researchers analyzed data from nearly 26,000 patients, finding that increased levels of soluble Aβ42 correlated with slower Alzheimer's progression during treatment with these monoclonal antibodies. • The study authors propose alternative therapies focused on boosting soluble Aβ42 levels directly, rather than solely targeting amyloid plaques, which may have long-term risks.
